

Title (en)

ANTI-CANCER REGIMEN

Title (de)

ANTIKREBSTERAPIE

Title (fr)

RÉGIME ANTI-CANCER

Publication

EP 2661173 A1 20131113 (EN)

Application

EP 11854601 A 20110131

Priority

- US 98484311 A 20110105
- US 2011023090 W 20110131

Abstract (en)

[origin: EP3141117A1] The invention provides a modified citrus pectin (MCP) for use in a method of enhancing the activation of T-cytotoxic suppressor lymphocytes by a mammal in response to an immune challenge, comprising administering to said mammal an amount of MCP effective to increase T-cytotoxic suppressor lymphocyte activation by said mammal, as compared with the level of activation by said mammal in the absence of administration of said MCP.

IPC 8 full level

A01N 31/04 (2006.01); **A61K 31/05** (2006.01); **A61K 31/065** (2006.01)

CPC (source: EP US)

A61K 31/05 (2013.01 - EP US); **A61K 31/732** (2013.01 - EP US); **A61K 39/39** (2013.01 - EP US); **A61K 45/06** (2013.01 - EP US);
A61P 35/00 (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 35/04** (2017.12 - EP); **A61P 37/04** (2017.12 - EP);
A61K 2039/55583 (2013.01 - EP US)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

EP 3141117 A1 20170315; EP 3141117 B1 20210303; AU 2011353785 A1 20130822; AU 2011353785 B2 20150604; CA 2825989 A1 20120712;
CA 2825989 C 20180109; EP 2661173 A1 20131113; EP 2661173 A4 20150304; EP 2661173 B1 20161207; ES 2613949 T3 20170529;
US 2012171228 A1 20120705; US 8916541 B2 20141223; WO 2012094030 A1 20120712

DOCDB simple family (application)

EP 16196059 A 20110131; AU 2011353785 A 20110131; CA 2825989 A 20110131; EP 11854601 A 20110131; ES 11854601 T 20110131;
US 2011023090 W 20110131; US 98484311 A 20110105